Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) Operating Expenses (2023 - 2024)

Sagimet Biosciences has reported Operating Expenses over the past 2 years, most recently at $18.2 million for Q4 2024.

  • Quarterly results put Operating Expenses at $18.2 million for Q4 2024, up 92.21% from a year ago — trailing twelve months through Dec 2024 was $54.5 million (up 66.32% YoY), and the annual figure for FY2025 was $56.9 million, up 4.47%.
  • Operating Expenses for Q4 2024 was $18.2 million at Sagimet Biosciences, up from $16.9 million in the prior quarter.
  • Over the last five years, Operating Expenses for SGMT hit a ceiling of $18.2 million in Q4 2024 and a floor of $6.8 million in Q1 2023.